Pfizer Wins FDA Approval for First Maternal RSV Shot to Protect Infants 8/22/2023

Teva to Pay $225M in DOJ Generic Drug Price-Fixing Settlement 8/22/2023

Industry Ties to Patient Advocacy Board Members, Execs Raise Concerns 8/22/2023

Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions 8/22/2023

Fulcrum’s Sickle Cell Trial Given Greenlight to Proceed After Hold 8/22/2023

DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.

Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair.

Gilead’s Magrolimab Again Placed on Partial Clinical Hold by FDA 8/21/2023

Roche, Exelixis’ Drug Combo Bounces Back with Late-Stage Prostate Cancer Win 8/21/2023

Moderna, CARsgen Join Forces Combining mRNA Cancer Vaccine with CAR T 8/21/2023

Regeneron Expands Eylea’s Label with High-Dose Approval 8/21/2023

CRISPR Shows Preclinical Promise in Treating Alzheimer’s, Challenges Persist 8/21/2023

FDA Pilot Program for Cancer Diagnostics Met with Skepticism 8/21/2023

AbbVie (NYSE: ABBV) announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

People who adhere to a Mediterranean lifestyle - which includes a diet rich in fruits, vegetables, and whole grains; healthy eating habits like limiting added salts and sugars; and habits promoting adequate rest, physical activity, and socialization - have a lower risk of all-cause and cancer mortality, according to a new study led by La Universidad Autónoma de Madrid and Harvard T.H. Chan School of Public Health.

Selecta Biosciences Halts Pipeline Investments, Focuses on Gout Treatment 8/17/2023

Boehringer Initiates Phase III Obesity Trials, Seeks to Challenge Novo and Lilly 8/17/2023

FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease 8/17/2023

Federal Appeals Court Rules for Tighter Restrictions on Abortion Pill 8/17/2023

Chimerix’s Drug Candidate Improves Survival for Patients with Incurable Brain Tumor 8/17/2023

Incubators Offer Staffing Support for Startups 8/17/2023